Why the study?
Despite high morbidity, mortality, and growing prevalence, few effective treatments are identified for HFpEF, highlighting a need to review current understanding of pathophysiologic mechanisms and treatment strategies.
This review highlights the pathophysiologic mechanisms of HFpEF and emphasizes the need for improved phenotyping to individualize treatment given the current lack of targeted therapies.
Approximately half of all patients with heart failure (HF) have a preserved ejection fraction, and the prevalence is growing rapidly given the aging population in many countries and the rising prevalence of obesity, diabetes, and hypertension. Functional capacity and quality of life are severely impaired in heart failure with preserved ejection fraction (HFpEF), and morbidity and mortality are high. In striking contrast to HF with reduced ejection fraction, there are few effective treatments currently identified for HFpEF, and these are limited to decongestion by diuretics, promotion of a healthy active lifestyle, and management of comorbidities. Improved phenotyping of subgroups within the overall HFpEF population might enhance individualization of treatment. This review focuses on the current understanding of the pathophysiologic mechanisms underlying HFpEF and treatment strategies for this complex syndrome.
No takes yet. Share an insight, caveat, or question.
Omote et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: